Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
Abstract
Prostate cancer is radiosensitive. Prostate‐specific membrane antigen (PSMA) is selectively overexpressed on advanced, castration‐resistant tumors. Lutetium‐177–labeled anti‐PSMA monoclonal antibody J591 (177Lu‐J591) targets prostate cancer with efficacy and dose‐response/toxicity data when delivered as a single dose. Dose fractionation may allow higher doses to be administered safely.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 23, 2019
- Source ID
- 10.1002/cncr.32072
Entities
People
- Ana M. Molina
- David M. Nanus
- Himisha Beltran
- Jaspreet S. Batra
- Joseph Osborne
- Linda Lam
- Neil H Bander
- Paul J. Christos
- Scott T Tagawa
- Shankar Vallabhajosula
- Stanley J. Goldsmith
- Yuliya S. Jhanwar
Organizations
- Dana–Farber Cancer Institute
- National Institutes of Health
- United States Department of Defense
- Weill Cornell Medicine